Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Interferon therapy in rheumatic diseases: state-of-the-art 2010

Kötter, Inaa; Hamuryudan, Vedatb; Öztürk, Zafer Ec; Yazici, Hasanb

Current Opinion in Rheumatology: May 2010 - Volume 22 - Issue 3 - p 278–283
doi: 10.1097/BOR.0b013e3283368099
Clinical therapeutics: Edited by Gerd Burmester and Thomas Dörner

Purpose of review Interferons are natural glycoproteins that have antiviral, antiproliferative and immune regulatory functions. They are not only involved in the pathogenesis of certain autoimmune conditions but are also useful in the treatment of some rheumatologic disorders, notably Behçet's syndrome.

Recent findings Interferon alpha (IFNα) has been recommended for severe eye involvement in Behçet's syndrome, especially when there is a significant drop in visual acuity and/or retinal involvement. It can induce a high rate of complete remission that may also persist after its discontinuation. When given early at the beginning, interferon might be effective in ameliorating the attacks of familial Mediterranean fever resistant to colchicine treatment. The combination of PEGylated IFNα with ribavirin and rituximab emerges as a novel and promising treatment providing complete clinical response and viral clearance in hepatitis C virus-associated mixed cryoglobulinemia. Limited data also suggest that interferon may induce remissions in Churg-Strauss patients who fail to respond to conventional immunosuppressive treatment.

Summary Among several rheumatologic diseases, IFNα has found more widespread use in Behçet's syndrome and hepatitis C virus-associated mixed cryoglobulinemia despite a paucity of formal studies. Patients should be carefully monitored for the frequent and dose-dependent adverse effects.

aDepartment of Internal Medicine II (Oncology, Haematology, Immunology, Rheumatology, Pulmonology), University Hospital, Tübingen, Germany

bDepartment of Rheumatology, Division of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey

cClinical Development MedImmune, LLC, Gaithersburg, Maryland, USA

Correspondence to Hasan Yazici, MD, Department of Rheumatology, Division of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey Tel: +90 212 4143200 x1971; fax: +90 212 5890808; e-mail:

© 2010 Lippincott Williams & Wilkins, Inc.